Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist
Tulobuterol patch (Hokunalin™ Tape), which contains a β2-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides with the morning dip in respiratory...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2012-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015302161 |
| _version_ | 1818057271844798464 |
|---|---|
| author | Gen Tamura Masakazu Ichinose Yoshinosuke Fukuchi Terumasa Miyamoto |
| author_facet | Gen Tamura Masakazu Ichinose Yoshinosuke Fukuchi Terumasa Miyamoto |
| author_sort | Gen Tamura |
| collection | DOAJ |
| description | Tulobuterol patch (Hokunalin™ Tape), which contains a β2-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides with the morning dip in respiratory function. The use of the patch also prevents excessive increase in blood drug concentrations, thereby reducing the incidence of systemic adverse reactions. Since 1998, when it was first approved in Japan and worldwide, the tulobuterol patch has been used widely in the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD), and evidence collected since it was approved has confirmed its clinical efficacy and safety. Because the patch is easy to use and requires only once-daily application, treatment adherence of patients using the patch is good. In this article, we discuss the rationale behind the development of the tulobuterol patch, evaluate data on its clinical efficacy and safety in the treatment of asthma and COPD, and examine the treatment adherence in individuals using the patch. |
| first_indexed | 2024-12-10T12:42:05Z |
| format | Article |
| id | doaj.art-2e26ceaa899848da8fa2d7b137950de6 |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-12-10T12:42:05Z |
| publishDate | 2012-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-2e26ceaa899848da8fa2d7b137950de62022-12-22T01:48:30ZengElsevierAllergology International1323-89302012-01-0161221922910.2332/allergolint.11-RA-0358Transdermal Tulobuterol Patch, a Long-Acting β2-AgonistGen Tamura0Masakazu Ichinose1Yoshinosuke Fukuchi2Terumasa Miyamoto3Airway Institute in Sendai Co., Ltd., Miyagi, Tokyo, Japan.Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Tokyo, Japan.Visiting Professor at Juntendo University, Tokyo, Japan.Japan Clinical Allergy Research Institute, Tokyo, Japan.Tulobuterol patch (Hokunalin™ Tape), which contains a β2-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides with the morning dip in respiratory function. The use of the patch also prevents excessive increase in blood drug concentrations, thereby reducing the incidence of systemic adverse reactions. Since 1998, when it was first approved in Japan and worldwide, the tulobuterol patch has been used widely in the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD), and evidence collected since it was approved has confirmed its clinical efficacy and safety. Because the patch is easy to use and requires only once-daily application, treatment adherence of patients using the patch is good. In this article, we discuss the rationale behind the development of the tulobuterol patch, evaluate data on its clinical efficacy and safety in the treatment of asthma and COPD, and examine the treatment adherence in individuals using the patch.http://www.sciencedirect.com/science/article/pii/S1323893015302161adherenceasthmaCOPDtransdermal patchtulobuterol |
| spellingShingle | Gen Tamura Masakazu Ichinose Yoshinosuke Fukuchi Terumasa Miyamoto Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist Allergology International adherence asthma COPD transdermal patch tulobuterol |
| title | Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist |
| title_full | Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist |
| title_fullStr | Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist |
| title_full_unstemmed | Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist |
| title_short | Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist |
| title_sort | transdermal tulobuterol patch a long acting β2 agonist |
| topic | adherence asthma COPD transdermal patch tulobuterol |
| url | http://www.sciencedirect.com/science/article/pii/S1323893015302161 |
| work_keys_str_mv | AT gentamura transdermaltulobuterolpatchalongactingb2agonist AT masakazuichinose transdermaltulobuterolpatchalongactingb2agonist AT yoshinosukefukuchi transdermaltulobuterolpatchalongactingb2agonist AT terumasamiyamoto transdermaltulobuterolpatchalongactingb2agonist |